Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. Stifel 2024 Healthcare Conference Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Monday, November 18 at 3:35 p.m. Eastern Time. A webcast will be accessible through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact

Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. "We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute treatment of social anxiety disorder," said Shawn Singh, Ch

Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic intranasal pherine product candidates in its neuroscience pipeline, itruvone in Phase 2 development for major depressive disorder and hormone-free PH80 in Phase 2 development for the management of vasomotor symptoms (hot flashes) due to menopause,

Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update Conference Call Date: Thursday, November 7, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-800-717-1738 TOLL/International Dial-in: 1-646-307-1865 Conference ID: 1196845 Webcast: https://viavid.webcasts.com/s

Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget

Next step in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder achieved as planned Vistagen (NASDAQ:VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in its PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray in U.S. registration-directed Phase 3 development for the acute treatment of social anxiety disorder (SAD). "With the initiation of PALISADE-4 as planned, we have achieved anot

PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, and provided a corporate update. "Building on the success of our PALISADE-2 Phase 3 trial of fasedienol, our rapid-onset, non-systemic pherine nasal spray for the acute treatment of social anxiety disorder, our top priority remains driving forward our

Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Tuesday, August 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 first quarter ended June 30, 2024 and provide a corporate update. Event: Vistagen Fiscal Year 2025 First Quarter Corporate Update Conference Call Date: Tuesday, August 13, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-877-

Vistagen (NASDAQ:VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global intellectual property portfolio after receiving multiple new patents related to the use of PH80 for the treatment of migraine. PH80 is a non-systemic, hormone-free investigational pherine nasal spray in development as a rapid-onset treatment for vasomotor symptoms (hot flashes) due to menopause, with the potential to also treat premenstrual dysphoric disorder, dysmenorrhea, and migraine. The new pate

Mental Health America's highest national certification enhances Vistagen's ongoing efforts to promote mental health throughout the U.S. Vistagen (NASDAQ:VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace. Vistagen's supportive workplace culture, mental health care benefits, emphasis on inclusion, and employee wellness programs ha

SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. "We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute treatment of social anxiety disorder," said Shawn Singh, Ch

Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update Conference Call Date: Thursday, November 7, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-800-717-1738 TOLL/International Dial-in: 1-646-307-1865 Conference ID: 1196845 Webcast: https://viavid.webcasts.com/s

PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, and provided a corporate update. "Building on the success of our PALISADE-2 Phase 3 trial of fasedienol, our rapid-onset, non-systemic pherine nasal spray for the acute treatment of social anxiety disorder, our top priority remains driving forward our

Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Tuesday, August 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 first quarter ended June 30, 2024 and provide a corporate update. Event: Vistagen Fiscal Year 2025 First Quarter Corporate Update Conference Call Date: Tuesday, August 13, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-877-

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update. Event: Vistagen Fiscal Year 2024 Corporate Update Conference Call Date: Tuesday, June 11, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-877-407-9716 TOLL/International Dial-in: 1-201-493-6779 Conference ID: 13746589 Webcast:

Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track PALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update. "Momentum from clinical and corporate milestones achieved through the end of last quarter have significantly advanced our efforts to develop and commercialize fasedienol as a potent

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 third quarter ended December 31, 2023 and provide a corporate update. Event: Vistagen Fiscal Year 2024 Third Quarter Corporate Update Conference Call Date: Tuesday, February 13, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-877-407-9716 TOLL/International Dial-in: 1-201-493-6779 Conference ID: 137

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, November 9, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to provide a corporate update and report results for its fiscal year 2024 second quarter ended September 30, 2023. Event: Vistagen Fiscal Year 2024 Second Quarter Corporate Update Conference Call Date: Thursday, November 9, 2023 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-800-245-3047 TOLL/International

Positive top-line results from Phase 3 PALISADE-2 trial of rapid-onset fasedienol (PH94B) nasal spray in social anxiety disorder (SAD) Itruvone (PH10) nasal spray now staged for Phase 2B clinical development as a stand-alone, non-systemic treatment for major depressive disorder (MDD) Positive exploratory Phase 2A trial of PH80 nasal spray provides new optimism for the acute treatment of moderate to severe vasomotor symptoms (hot flashes) in women due to menopause Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today prov

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and report results for its fiscal year 2024 first quarter ended June 30, 2023. Event: Vistagen Fiscal Year 2024 First Quarter Corporate Update Conference Call Date: Thursday, August 10, 2023 Time: 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) US Dial-in (Toll-free): 1-800-954-1051 TOLL/International Dial-in: 1

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

Cash and cash equivalents were $119.2 million as of March 31, 2024.

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participantsPH15 was safe and well-tolerated with an adverse event profile similar to placeboVistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placeb

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorderSocial anxiety disorder affects over 25 million AmericansVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD)."Initiating PALISADE-3 is another major milestone in our plan to develop and commercialize fasedienol as the first treatme

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume NVO CALL SWEEP BEARISH 04/19/24 $125.00 $149.6K 19 4.3K IOVA CALL SWEEP BULLISH 02/23/24 $10.00 $31.2

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 84.51 percent increase over losses of $(1.42) per share from the same period last year. The company reported quarterly sales of $411.40 thousand which missed the analyst consensus estimate of $544.50 thousand by 24.44 percent. This is a 129.06 percent increase over sales of $179.60 thousand the same period last year.

Vistagen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Tuesday, February 13, 2024 at 04:21 PM. Here's what investors need to know about the announcement. Earnings Vistagen Therapeutics beat estimated earnings by 26.67%, reporting an EPS of $-0.22 versus an estimate of $-0.3. Revenue was up $231 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.02 which was followed by a 11.07% drop in the share price the next day. To track all earnings releases for Vistagen Therapeutics visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. • Navios Maritime Partners (NYSE:NMM) is projected to report quarterly earnings at $2.62 per share on revenue of $334.79 million. • Restaurant Brands Intl (NYSE:QSR) is estimated to report quarterly earnings at $0.74 per share on revenue of $1.81 billion. • OrganiGram Holdings (NASDAQ:OGI) is projected to report quarterly loss at $0.13 per share on revenue of $37.77 million. • Hyatt Hotels (NYSE:H) is projected to report quarterly earnings at $0.29 per share on revenue of $1.86 billion. • InMode (NASDAQ:INMD) is likely to report quarterly

VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Tuesday, 2024-02-13. Here's what investors need to know before the announcement. Analysts estimate that VistaGen Therapeutics will report an earnings per share (EPS) of $-0.30. VistaGen Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.02, which was followed

Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101's robust effects similar to gabapentin but with a better side effect profilePhase 1 data demonstrate AV-101 is well-tolerated, with no meaningful difference in adverse events between AV-101 and placebo at any dose testedVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued a Notice of Intention to Grant a patent related to the use of A

Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget

Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V

Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen's Board of Directors the option to implement a future reverse stock split of the Company's issued and outstanding common stock, if necessary to maintain the Company's listing on the Nasdaq Capital Market, and Proposal No. 6 to allow for an amendment to the Company's Bylaws Vistagen Therapeutics, Inc. (NASDAQ:VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced results of voting and the partial adjournment of the Company's 2022 Annua

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer. Adler will oversee VistaGen's legal affairs and provide strategic guidance to its Executive Team and Board of Directors. "We are excited to welcome Reid to VistaGen's Executive Team," said Shawn Singh, Chief Executive Officer. "He is a visionary, trusted advisor and proven leader who brings deep legal experience across numerous domains as well a passion for helping

SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system ("CNS") disorders, today announced the appointment of Maggie FitzPatrick to its Board of Directors ("Board"), replacing Dr. Brian J. Underdown who recently retired from the Board. "Maggie is a highly-regarded public affairs strategist with extensive experience developing and executing multiple high impact customer-focused marketing communications initiatives for some of the world's la

SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system ("CNS") disorders, today announced the appointment of Mary L. Rotunno, J.D. to its Board of Directors ("Board"). "Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered nurse and transitioned to serving clients in health care law, both allowing her to pursue her steadfast commitment to helping others and advancing the futur

SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system ("CNS") disorders, today announced the appointment of Ann Cunningham as its Chief Commercial Officer. Ms. Cunningham has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing, and global life cycle product management expertise in roles across several healthcare markets, including neuropsychiatry and other CNS markets that VistaGen is pursuing. Sh

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system ("CNS") disorders, today announced the appointment of Joanne Curley, Ph.D. to its Board of Directors ("Board"). Following the appointment of Dr. Curley, VistaGen's Board will be comprised of seven directors. "Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas," said Shawn Singh, Chief Executive Officer of VistaGe